• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Eating and weight disorders: EWD >Integrated weight loss and cognitive behavioural therapy (CBT)for the treatment of recurrent binge eating and high body mass index:a randomized controlled trial
【24h】

Integrated weight loss and cognitive behavioural therapy (CBT)for the treatment of recurrent binge eating and high body mass index:a randomized controlled trial

机译：用于治疗复发性狂犬病的综合减肥和认知行为治疗（CBT）：随机对照试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose The association between binge eating and obesity is increasing. Treatments for disorders of recurrent binge eating comorbid with obesity reduce eating disorder (ED) symptoms, but not weight. This study investigated the efficacy and safety of introducing a weight loss intervention to the treatment of people with disorders of recurrent binge eating and a high body mass index (BMI). Methods A single-blind randomized controlled trial selected adults with binge eating disorder or bulimia nervosa and BMI≥27 to <40 kg/m~2. The primary outcome was sustained weight loss at 12-month follow-up. Secondary outcomes included ED symptoms. Mixed effects models analyses were conducted using multiple imputed datasets in the presence of missing data. Results Ninety-eight participants were randomized to the Health Approach to Weight Management and Food in Eating Disorders (HAPIFED) or to the Cognitive Behavioural Therapy-Enhanced (CBT-E). No between-group differences were found for percentage of participants achieving weight loss or secondary outcomes, except for reduction of purging behaviour, which was greater with HAPIFED (p = 0.016). Binge remission rates specifically at 12-month follow-up favoured HAPIFED (34.0% vs 16.7%; p = 0.049). Overall, significant improvements in the reduction of ED symptoms were seen in both groups and these were sustained at the 12-month follow-up. Conclusion HAPIFED was not superior to CBT-E in promoting clinically significant weight loss and was not significantly different in reducing most ED symptoms. No harm was observed with HAPIFED, in that no worsening of ED symptoms was observed. Further studies should test approaches that target both the management of ED symptoms and the high BMI. Level of evidence Level I, randomized controlled trial Trial registration US National Institutes of Health clinical trial registration number NCT02464345, date of registration 1 June 2015.
机译：None

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号